Latest News

Aclarion Adds to Strong Patent Portfolio with New U.S. Patent Application

Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration. Successful commercialization of IP holds the promise of giving physicians better data to make the critical decision as to whether antibiotic therapy or surgery is the preferred treatment option.   December 01, 2022, Broomfield, CO […]

Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor

October 24, 2022, Broomfield, CO – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Sigurd Berven M.D., Chief of Spine Service, Orthopaedic Surgery at University of California […]

Aclarion to Present at the LD Micro Main Event XV

Presentation on Tuesday, October 25th at 9:00 AM PT   Broomfield, CO, October 12, 2022 – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), announced today that it will […]

Aclarion Announces Participation at the NASS 37th Annual Meeting

Nociscan utilized within unprecedented NIH HEAL Initiative featured at NASS 2022 NociscanTM is the first evidence-supported SaaS platform to objectively analyze intradiscal pain Nociscan bridges major diagnostic void between MRI and provocative discography   October 10, 2022, Broomfield, CO – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is […]

John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor

  Aclarion Key Opinion Leader program supports focused strategy of building strong clinical evidence and payer community advocacy to drive adoption of NociscanTM solution   October 3, 2022, Broomfield, CO – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help […]

Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain

NIH funded Biomarkers for Evaluating Spine Treatments (BEST) Trial launching this quarter BEST to study the role of biomarkers in optimizing the treatment of chronic low back pain Nociscan to be commercially active across seven participating major academic medical centers   September 19, 2022, Broomfield, CO – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, […]

Request Info or Schedule a Demo

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Aclarion
8181 Arista Place,
Suite 100
Broomfield, CO 80021

info@aclarion.com

833-ASK-ACON (833-275-2266)